Palatin Technologies Stock Forecast, Price & News

Palatin Technologies (NYSEAMERICAN:PTN) Frequently Asked Questions

Is Palatin Technologies a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Palatin Technologies in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Palatin Technologies stock.
View analyst ratings for Palatin Technologies or view top-rated stocks.

Are investors shorting Palatin Technologies?

Palatin Technologies saw a decline in short interest during the month of December. As of December 31st, there was short interest totaling 6,850,000 shares, a decline of 40.4% from the December 15th total of 11,490,000 shares. Based on an average trading volume of 8,750,000 shares, the days-to-cover ratio is presently 0.8 days. Currently, 3.3% of the company's stock are short sold.
View Palatin Technologies' Short Interest.

When is Palatin Technologies' next earnings date?

Palatin Technologies is scheduled to release its next quarterly earnings announcement on Tuesday, February 15th 2022.
View our earnings forecast for Palatin Technologies.

How were Palatin Technologies' earnings last quarter?

Palatin Technologies, Inc. (NYSEAMERICAN:PTN) posted its quarterly earnings data on Monday, November, 15th. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.03). The biopharmaceutical company earned $0.16 million during the quarter. During the same period last year, the business posted ($0.02) earnings per share.
View Palatin Technologies' earnings history.

What price target have analysts set for PTN?

2 Wall Street analysts have issued 1-year price targets for Palatin Technologies' stock. Their forecasts range from $2.00 to $5.00. On average, they expect Palatin Technologies' stock price to reach $3.50 in the next twelve months. This suggests a possible upside of 790.6% from the stock's current price.
View analysts' price targets for Palatin Technologies or view top-rated stocks among Wall Street analysts.

Who are Palatin Technologies' key executives?

Palatin Technologies' management team includes the following people:

• Carl Spana, President, Chief Executive Officer & Director
• Stephen T. Wills, COO, CFO, Secretary, Treasurer & Executive VP
• Michael B. Raizman, Chief Medical Officer
• John Dodd, Senior Vice President-Preclinical Development
• James E. Hattersley, Senior Vice President-Business Development

Who are some of Palatin Technologies' key competitors?

Some companies that are related to Palatin Technologies include Xilio Therapeutics (XLO), Arbutus Biopharma (ABUS), Nature's Sunshine Products (NATR), ESSA Pharma (EPIX), Akebia Therapeutics (AKBA), Nkarta (NKTX), Khosla Ventures Acquisition (KVSA), Oramed Pharmaceuticals (ORMP), Applied Molecular Transport (AMTI), Geron (GERN), BioDelivery Sciences International (BDSI), Omeros (OMER), Avadel Pharmaceuticals (AVDL), Adagene (ADAG) and Vaccitech (VACC).
View all of PTN's competitors.

What other stocks do shareholders of Palatin Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Palatin Technologies investors own include (XXII), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), Trevena (TRVN), Alliqua Biomedical (ALQA), Catalyst Pharmaceuticals (CPRX), AVEO Pharmaceuticals (AVEO), ImmunoGen (IMGN), TherapeuticsMD (TXMD) and Actinium Pharmaceuticals (ATNM).

What is Palatin Technologies' stock symbol?

Palatin Technologies trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PTN."

How do I buy shares of Palatin Technologies?

Shares of PTN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Palatin Technologies' stock price today?

One share of PTN stock can currently be purchased for approximately $0.39.

How much money does Palatin Technologies make?

Palatin Technologies has a market capitalization of $90.92 million and generates $120 thousand in revenue each year. The biopharmaceutical company earns $-33.60 million in net income (profit) each year or ($0.15) on an earnings per share basis.

How many employees does Palatin Technologies have?

Palatin Technologies employs 20 workers across the globe.

What is Palatin Technologies' official website?

The official website for Palatin Technologies is www.palatin.com.

Where are Palatin Technologies' headquarters?

Palatin Technologies is headquartered at 4B Cedarbrook Dr, CRANBURY, NJ 08512-3641, United States.

How can I contact Palatin Technologies?

Palatin Technologies' mailing address is 4B Cedarbrook Dr, CRANBURY, NJ 08512-3641, United States. The biopharmaceutical company can be reached via phone at (609) 495-2200, via email at [email protected], or via fax at 609-495-2202.